Castleark Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Castleark Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$326K	Hold	730	–	–	0.01%	265
2025 Q4	$331K	Hold	730	–	–	0.01%	262
2025 Q3	$286K	Hold	730	–	–	0.01%	255
2025 Q2	$325K	Sell	730 -46,309	-98%	-$21.3M	0.01%	241
2025 Q1	$22.8M	Buy	47,039 +554	+1%	+$258K	0.79%	25
2024 Q4	$18.7M	Sell	46,485 -36,240	-44%	-$16.8M	0.65%	26
2024 Q3	$38.5M	Buy	82,725 +35,922	+77%	+$17.3M	1.57%	16
2024 Q2	$21.9M	Buy	46,803 +46,073	+6,311%	+$20M	0.9%	20
2024 Q1	$305K	Hold	730	–	–	0.01%	240
2023 Q4	$297K	Hold	730	–	–	0.01%	243
2023 Q3	$254K	Hold	730	–	–	0.01%	236
2023 Q2	$257K	Hold	730	–	–	0.01%	237
2023 Q1	$230K	Hold	730	–	–	0.01%	244
2022 Q4	$211K	Hold	730	–	–	0.01%	256
2022 Q3	$211K	Hold	730	–	–	0.01%	253
2022 Q2	$206K	Hold	730	–	–	0.01%	265
2022 Q1	$191K	Hold	730	–	–	0.01%	291
2021 Q4	$160K	Hold	730	–	–	0.01%	309
2021 Q3	$132K	Hold	730	–	–	0.01%	309
2021 Q2	$147K	Hold	730	–	–	﹤0.01%	312
2021 Q1	$157K	Hold	730	–	–	0.01%	306
2020 Q4	$173K	Sell	730 -200	-22%	-$45.9K	0.01%	309
2020 Q3	$253K	Hold	930	–	–	0.01%	302
2020 Q2	$270K	Sell	930 -104,130	-99%	-$28.2M	0.01%	289
2020 Q1	$25M	Buy	105,060 +38,240	+57%	+$8.77M	1.48%	14
2019 Q4	$14.6M	Buy	66,820 +65,890	+7,085%	+$13.3M	0.59%	41
2019 Q3	$158K	Sell	930 -10,180	-92%	-$1.8M	0.01%	319
2019 Q2	$2.04M	Sell	11,110 -15,720	-59%	-$2.75M	0.08%	219
2019 Q1	$4.93M	Hold	26,830	–	–	0.19%	157
2018 Q4	$4.45M	Hold	26,830	–	–	0.19%	156
2018 Q3	$5.17M	Hold	26,830	–	–	0.15%	194
2018 Q2	$4.56M	Hold	26,830	–	–	0.14%	198
2018 Q1	$4.37M	Hold	26,830	–	–	0.14%	200
2017 Q4	$4.02M	Hold	26,830	–	–	0.12%	211
2017 Q3	$4.08M	Hold	26,830	–	–	0.13%	206
2017 Q2	$3.46M	Hold	26,830	–	–	0.11%	212
2017 Q1	$2.93M	Hold	26,830	–	–	0.09%	242
2016 Q4	$1.98M	Hold	26,830	–	–	0.06%	263
2016 Q3	$2.34M	Hold	26,830	–	–	0.07%	249
2016 Q2	$2.31M	Hold	26,830	–	–	0.07%	255
2016 Q1	$2.13M	Hold	26,830	–	–	0.07%	245
2015 Q4	$3.38M	Sell	26,830 -4,000	-13%	-$483K	0.1%	223
2015 Q3	$3.21M	Hold	30,830	–	–	0.1%	222
2015 Q2	$3.81M	Hold	30,830	–	–	0.1%	224
2015 Q1	$3.64M	Hold	30,830	–	–	0.09%	233
2014 Q4	$3.66M	Sell	30,830 -1,000	-3%	-$113K	0.09%	185
2014 Q3	$2.25M	Hold	31,830	–	–	0.06%	215
2014 Q2	$3.01M	Hold	31,830	–	–	0.08%	200
2014 Q1	$2.25M	Hold	31,830	–	–	0.06%	215
2013 Q4	$2.37M	Buy	31,830 +1,000	+3%	+$69.6K	0.07%	206
2013 Q3	$3.46M	Sell	30,830 -6,500	-17%	-$517K	0.1%	195
2013 Q2	$2.99M	Buy	+37,330	New	+$2.75M	0.1%	162

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Castleark Management's VRTX Position: Q1 2026 in Review

Castleark Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 730 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #265.

Castleark Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.5M in Q3 2024. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Castleark Management held 730 shares of Vertex Pharmaceuticals worth $326K as of Q1 2026.
Castleark Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Castleark Management's portfolio in Q1 2026, its #265 holding.
Castleark Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Castleark Management's Vertex Pharmaceuticals position peaked at $38.5M in Q3 2024.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.